Aclaris Therapeutics to Participate in the William Blair Biotech Focus Conference 2021
08 juil. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Announces Pricing of Public Offering of Common Stock
09 juin 2021 19h55 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Announces Proposed Public Offering of Common Stock
08 juin 2021 16h15 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Positive Preliminary Topline Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
08 juin 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
ATI-1777 Achieved Statistically Significant Result in the Primary Efficacy Endpoint at Week 4Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor ApproachATI-1777 was Generally Well...
Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
17 mai 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory...
Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update
07 mai 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
Data from Phase 2a Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis Expected in Second Quarter of 2021Advancing ATI-450 with Planned Initiation of Phase 2b Trial for Moderate to Severe...
Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis
15 mars 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
Enrollment CompletedData Expected Mid-Year 2021 WAYNE, Pa., March 15, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
25 févr. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
Positive Preliminary Topline Data for ATI-450, an Investigational Oral MK2 Inhibitor, in Moderate to Severe Rheumatoid Arthritis Announced in January 2021ATI-450 Data Support New Oral Approach for the...
Aclaris Therapeutics to Participate in Upcoming Investor Conferences
22 févr. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
10 févr. 2021 07h00 HE
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...